HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study.

Abstract
Aspirin should be used for the prevention of cardiovascular (CV) events by the risk-benefit balance. This study was conducted to clarify CV and bleeding events in Japanese aspirin users with a history of CV diseases. This study was a prospective, nationwide, multicenter cooperative registry of Japanese patients with CV diseases at risk of thromboembolism who were taking aspirin (75-325 mg) for at least 1 year. We observed major CV and bleeding events during follow-up. Patients with history of ischemic stroke (IS), transient ischemic attack (TIA), coronary artery disease (CAD), atrial fibrillation (AF), and venous thromboembolism (VTE) were included and analyzed in this sutdy. CV events included IS, TIA, CAD, CV death, angioplasty or stenting, and hospitalization because of CV disease. Bleeding events included major bleeding requiring hospitalization and/or blood transfusion. A total of 1506 patients were categorized into IS/TIA (N = 540), CAD (N = 632), and AF/VTE (N = 232). Among them, 101 patients had two or more categories. CV and bleeding events occurred in 61 (3.82%/year) and 15 patients (0.93%/year), respectively. The annual rates of CV and bleeding events were 2.81% and 0.93% in IS/TIA, 5.32% and 0.75% in CAD, 1.15% and 1.15% in AF/VTE, and 6.44% and 0.91% in two or more disease categories, respectively. The Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study clarified the rates of major CV and bleeding events with long-term use of aspirin in patients with prior CV diseases in real-world clinical practice. The risk-benefit balance of aspirin was acceptable in patients with IS/TIA, CAD, and multiple CV diseases but not in those with AF/VTE.Trial Registration: The MAGIC Study is registered at UMIN Clinical Trial Registry (www.umin.ac.jp/ctr/index-j.htm), number UMIN000000750.
AuthorsShinichiro Uchiyama, Shinya Goto, Hideki Origasa, Naomi Uemura, Kentaro Sugano, Hideyuki Hiraishi, Kazuyuki Shimada, Yasushi Okada, Yasuo Ikeda, MAGIC Study Group
JournalHeart and vessels (Heart Vessels) Vol. 35 Issue 2 Pg. 170-176 (Feb 2020) ISSN: 1615-2573 [Electronic] Japan
PMID31446462 (Publication Type: Journal Article, Multicenter Study, Observational Study)
Chemical References
  • Fibrinolytic Agents
  • Aspirin
Topics
  • Aged
  • Aspirin (administration & dosage, adverse effects)
  • Cardiovascular Diseases (diagnosis, drug therapy, epidemiology)
  • Drug Administration Schedule
  • Female
  • Fibrinolytic Agents (administration & dosage, adverse effects)
  • Hemorrhage (chemically induced, epidemiology)
  • Humans
  • Incidence
  • Japan (epidemiology)
  • Male
  • Middle Aged
  • Prospective Studies
  • Registries
  • Risk Assessment
  • Risk Factors
  • Thromboembolism (diagnosis, epidemiology, prevention & control)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: